The Face of Global Healthcare in the Year 2020

By Admin
For many years the industry has been criticized as a broken system, struggling to meet the ever-changing challenges that it faces. However, positive st...

For many years the industry has been criticized as a broken system, struggling to meet the ever-changing challenges that it faces. However, positive steps are being made by providers from around the world to correct these problems, with technology leading the way.  

By the year 2020 the healthcare industry will be a highly connected environment powered by large data networks, cloud computing, and mobile devices. Leading to a widespread increase in connected networks, providing seamless integration between care providers, patients, pharmaceutical companies, health insurers, and other invested interests from around the world. Within this model care will become more patient-centric, less expensive to provide, and more innovative.

As ever, developments within the industry are being pushed by regulatory pressures and pulled by changing demands such as the ageing population or expanding emerging markets in Africa and Asia. However, it is modern advances in technology that will be capable of accelerating the medtech industry ahead of these trends in the coming years.

These include integrated communication networks that facilitate remote delivery of health services. Cloud computing and machine-to-machine innovations now provide an easy launching point for getting these networks online. However, for the year 2020 to bring a better healthcare world, the industry needs to start laying the foundations now.

Accenture has identified a three-phase approach to help medical technology providers effectively re-engineer their current business strategies in order to deliver these goals by 2020.

Horizon Scan 2020+

Providers should first conduct a ‘horizon scan’ whereby a senior management team with knowledge in various disciplines should study the potential that certain technologies will deliver to their profit margins, such as; new healthcare eco-systems, distributed imaging systems, distributed diagnostics, global shared diagnostics services models, global devices portals, handheld imaging and diagnostic systems clinical decision support hubs, fully integrated micro monitoring, and health system solutions.

These medical technology providers should then do secondary research to identify the relevant markets, environments, and competitive trends.

Disruption and Engagement

During this phase, insight and output on the future direction of the healthcare industry are collected and prioritized for further refinement. Open workshops help develop breakthrough disruptive platforms that can best execute these ideas. This concept should encompass a solution, the proposition, and the estimated windfall the concept will return to the company.

Putting Innovation into Action

After studying the healthcare industry and generating disruptive strategies in response, this next stage consolidates everything together into an actionable innovation plan. Experts vet the innovation concept considering the implications it will have on the company’s strategic vision and positioning, for better or worse.

Read the full Accenture report here.

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma